Amarin is going to have to get the stock price up on its own. Until they can prove that V can be a big seller no one will be interested. Hopefully the PFE - Canada experiment shows promise.
Sstyles. First of all I am not predicting a BO. My point is that a BO by a BP would be the only way to optimize the uptake of the drug. If a BO never happens then a great drug will be "laid to waste." My speculation is that if a BO deal could be agreed upon, I think the price would have to be somewhere between $22 and $24. But that is just my opinion. My fear is that if KM decides to GIA forever, he will not be able to gain enough sales traction quickly enough to produce a good return. Management would simply continue to issue themselves more free shares that would negate any growth. Because Europe is somewhat protected a BP could make serious money if they acquired AMRN soon enough to allow them to really detail the drug as various jurisdictions open up for sales. The key question may be does some Eurocentric BP need Vascepa to sell? (I suspect if a BP really needed it they would acquire it.)
News 
Market Data 
Discover 
